Drugs / CD19/CD20/BCMA CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06732232 | Dec 2024 → Dec 2027 expected | plasma cell myeloma, refractory malignant neoplasm | Shanghai Cell Therapy Group Co.,Ltd | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/CD20/BCMA CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06732232 ↗ |
| Modality | Cell therapy | “autologouschimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA” NCT06732232 ↗ |
| Route | Intravenous | “CD19/CD20/BCMA CAR T cells by intravenous (IV) injection” NCT06732232 ↗ |
| Target | CD19 | “autologouschimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA” NCT06732232 ↗ |
| Target | CD22 | “autologouschimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA” NCT06732232 ↗ |